Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study-Reference-Cited by-同舟云学术

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

Published:2021-10-22 Issue:6566 Volume:374 Page:472-478
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Hastie Kathryn M.¹^ORCID,Li Haoyang¹^ORCID,Bedinger Daniel²^ORCID,Schendel Sharon L.¹^ORCID,Dennison S. Moses³^ORCID,Li Kan³,Rayaprolu Vamseedhar¹^ORCID,Yu Xiaoying¹^ORCID,Mann Colin¹^ORCID,Zandonatti Michelle¹^ORCID,Diaz Avalos Ruben¹,Zyla Dawid¹^ORCID,Buck Tierra¹^ORCID,Hui Sean¹,Shaffer Kelly¹,Hariharan Chitra¹^ORCID,Yin Jieyun¹^ORCID,Olmedillas Eduardo¹,Enriquez Adrian¹^ORCID,Parekh Diptiben¹^ORCID,Abraha Milite³^ORCID,Feeney Elizabeth³^ORCID,Horn Gillian Q.³^ORCID,Aldon Yoann⁴^ORCID,Ali Hanif⁵^ORCID,Aracic Sanja⁶^ORCID,Cobb Ronald R.⁷,Federman Ross S.⁸,Fernandez Joseph M.⁹^ORCID,Glanville Jacob¹⁰,Green Robin⁸^ORCID,Grigoryan Gevorg⁸^ORCID,Lujan Hernandez Ana G.¹¹^ORCID,Ho David D.¹²^ORCID,Huang Kuan-Ying A.¹³^ORCID,Ingraham John⁸^ORCID,Jiang Weidong¹⁴^ORCID,Kellam Paul¹⁵¹⁶^ORCID,Kim Cheolmin¹⁷^ORCID,Kim Minsoo¹⁷,Kim Hyeong Mi¹⁷,Kong Chao¹⁸,Krebs Shelly J.¹⁹^ORCID,Lan Fei⁹²⁰,Lang Guojun¹⁸,Lee Sooyoung¹⁷^ORCID,Leung Cheuk Lun⁸,Liu Junli¹⁴^ORCID,Lu Yanan⁹²¹,MacCamy Anna²²^ORCID,McGuire Andrew T.²²^ORCID,Palser Anne L.¹⁵^ORCID,Rabbitts Terence H.⁵²³^ORCID,Rikhtegaran Tehrani Zahra²⁴^ORCID,Sajadi Mohammad M.²⁴^ORCID,Sanders Rogier W.⁴^ORCID,Sato Aaron K.¹¹,Schweizer Liang²⁵^ORCID,Seo Jimin¹⁷^ORCID,Shen Bingqing²⁵^ORCID,Snitselaar Jonne L.⁴,Stamatatos Leonidas²²^ORCID,Tan Yongcong¹⁸,Tomic Milan T.²⁶^ORCID,van Gils Marit J.⁴^ORCID,Youssef Sawsan¹⁰,Yu Jian¹²^ORCID,Yuan Tom Z.¹¹^ORCID,Zhang Qian²⁵^ORCID,Peters Bjoern¹²⁷^ORCID,Tomaras Georgia D.³^ORCID,Germann Timothy²^ORCID,Saphire Erica Ollmann¹²⁷,

Affiliation:

1. Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.

2. Carterra, 825 N. 300 W. Ste C309, Salt Lake City, UT 84103, USA.

3. Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.

4. Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, 1105 AZ Amsterdam, Netherlands.

5. Quadrucept Bio, Ltd., Cambridge CB23 6DW, UK.

6. Myrio Therapeutics Pty, Ltd., 1 Dalmore Drive, Scoresby, VIC 3179, Australia.

7. National Resilience, Inc., 13200 NW Nano Ct., Alachua, FL 32615, USA.

8. Generate Biomedicines, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USA.

9. Activemotif, Inc., 1914 Palomar Oaks Way, Suite 150, Carlsbad, CA 92008, USA.

10. Centivax, Inc., 201 Gateway Blvd., Floor 1, South San Francisco, CA 94080, USA.

11. Twist Bioscience, 681 Gateway Blvd., South San Francisco, CA 94080, USA.

12. Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, 701 West 168th St., HHSC 1102, New York, NY 10032, USA.

13. Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital and Research Center for Emerging Viral Infections, Chang Gung University, Taoyuan, Taiwan.

14. Shanghai Henlius Biotech, Inc., 9/F, Innov Tower, Zone A, no. 1801 Hongmei Road, Xuhui District, Shanghai, China.

15. Kymab, Ltd., The Bennet Building, Babraham Research Campus, Cambridge CB22 3AT, UK.

16. Department of Infectious Disease, Imperial College, London SW7 2AZ, UK.

17. Celltrion, Inc., Department of Research and Development, 23 Academy-ro Yeonsu-gu Incheon, Republic of Korea.

18. Sanyou Biopharmaceuticals Co., Ltd., no. 188 Xinjunhuan Road, Building 6B-C, 3rd Floor, Minhang District, Shanghai 201114, China.

19. Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.

20. Shanghai Key Laboratory of Medical Epigenetics, International Laboratory of Medical Epigenetics and Metabolism, Ministry of Science and Technology, Institutes of Biomedical Sciences, Fudan University, Shanghai, China.

21. AbCipher Biotechnology, 188 Xinjun Ring Road, Building 2, 4th Floor, Minhang District, Shanghai 201114, China.

22. Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA, USA.

23. Institute of Cancer Research, Centre for Cancer Drug Discovery, London SM2 5NG, UK.

24. Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, Baltimore, MD 21201, USA.

25. HiFiBiO, Inc., 237 Putnam Avenue, Cambridge, MA 02139, USA.

26. National Resilience, Inc., 2061 Challenger Dr., Alameda, CA 94501, USA.

27. Department of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.

Abstract

Community of antibodies against COVID-19 The severe acute respiratory syndrome coronavirus 2 spike protein is the basis of many vaccines and is a primary target of neutralizing antibodies after COVID-19 infection. The Coronavirus Immunotherapeutic Consortium (CoVIC), comprising 56 partners across the world, has analyzed a panel of 269 monoclonal antibodies (mAbs) and, on the basis of competition profiles, sorted 186 mAbs that target the receptor binding domain into seven communities. Hastie et al . went on to structurally analyze representative antibody binding and used pseudovirus neutralization assays to study the effect of spike mutations on antibody function, including the combinations of mutations found in certain variants of concern. These results are important to guide both treatment and prevention efforts. —VV

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference56 articles.

1. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

2. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

3. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

4. CDC Science Brief: Emerging SARS-CoV-2 Variants (2021); www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scientific-brief-emerging-variants.html.

5. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020

Cited by 251 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Receptor binding mechanism and immune evasion capacity of SARS-CoV-2 BQ.1.1 lineage;Virology;2024-12

2. Structural review of SARS-CoV-2 antiviral targets;Structure;2024-09

3. Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting;2024-08-15

4. Spike structures, receptor binding, and immune escape of recently circulating SARS-CoV-2 Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants;Structure;2024-08

5. Safety and durability of mRNA-1273–induced SARS-CoV-2 immune responses in adolescents: results from the phase 2/3 TeenCOVE trial;eClinicalMedicine;2024-08